MedTrace Logo

Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy

NCT01893788 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2013-07-22

No results posted yet for this study

Summary

The primary objective of this study is to determine which treatment will be more effective to reduce left ventricular mass in hypertensive patients with left ventricular hypertrophy comparing aliskiren and eplerenone.

Conditions

  • Hypertensive Left Ventricular Hypertrophy

Interventions

DRUG

Aliskiren

Aliskiren: 150 to 300 mg daily for 48 weeks

DRUG

Eplerenone

50 to 100 mg daily for 48 weeks

Sponsors & Collaborators

  • Nagoya University

    lead OTHER

Principal Investigators

  • Toyoaki Murohara, MD, PhD · Department of Cardiology, Nagoya University Graduate School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2016-03-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01893788 on ClinicalTrials.gov